Last edition
News about "Phase 1 clinical trials"
GSK to Acquire Chimagen's Trispecific T-Cell Engager for Multiple Myeloma
GSK agrees to acquire global rights to Chimagen Biosciences’ investigational trispecific T-cell engager for multiple myeloma in a deal valued at up to USD 750 million.
Phase 1 Clinical Trials | 16/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members